GRFSGrifols, S.A.
Price
-24%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, nothing alarming, growth steady, the market undecided.
We are one of the leading global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value.
In the company’s own words · 20-F filed Apr 17, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
For the full year FY2024, revenue was €7.21B (+9.4% year on year) and net income €157M.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, General
Ranks #6 of 7 by RyuScore